Introduction {#Sec1}
============

The COVID-19 pandemic with at more than 6.5 million cases worldwide and more than 397,000 fatalities (date 07 June 2020) is an unprecedent situation for society and health care \[[@CR1]\]. Although, most infections are not severe \[[@CR2]--[@CR5]\], about 5% develop a critical disease with respiratory failure, shock, or multiorgan dysfunction \[[@CR5]\]. The overall case fatality rate is estimated at around 0.7 to 2.3% \[[@CR5], [@CR6]\]. Pneumonia appears to be the most frequent severe manifestation of infection \[[@CR2], [@CR6]\]. Additional COVID-19-induced coagulopathy might play an important role in COVID-19-related death \[[@CR7]\].

Whereas the majority of patients presents with mild symptoms \[[@CR2]--[@CR5]\] and can be treated as outpatients, severely ill COVID-19 patients and patients with similar symptoms cross their way in the emergency department (ED). Due to the high infectiousness of SARS-Cov-2, it is crucial to separate patients with suspicion of COVID-19 and other patients as soon as possible to avoid further spread of the infection. Especially, the variety of symptoms in COVID-19 patients is challenging for the primary triage in the ED: fever, fatigue, dry cough, anorexia, myalgias, dyspnea, sputum production, and olfactory and taste disorders are the most frequent symptoms \[[@CR2], [@CR8]\].

Particular laboratory features like lymphopenia, elevated liver enzymes, elevated lactate dehydrogenase, C-reactive protein, elevated D-dimer, elevated prothrombin time, elevated troponin, and acute kidney injury have been associated with worse outcomes \[[@CR9], [@CR10]\]. However, data about possible parameters to distinguish between COVID-19 and other patients are sparse.

Therefore, we conducted a retrospective analysis to identify clinical parameters and laboratory features which could improve early triage between patients with and without COVID-19.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We performed a retrospective, single-center case-control study that included all inpatient patients with possible symptoms of COVID-19 who were admitted to the emergency department between March and April 2020 and were tested by nasopharyngeal swab for SARS-Cov-2. At least one symptom upon arrival to the ED out of the following was required for inclusion: dyspnea, sore throat, cough, fever, headache, fatigue, myalgia, chest pain, nausea, diarrhea, and/ or dysgeusia. Patients without any of the mentioned symptoms were excluded as well as those without valid nasopharyngeal swab results. Our study was approved by the institutional ethics committee and informed consent was waived (file number: 20-9310-BO, date: 6 May 2020). The study was registered at the German Clinical Trials registry (trial number: DRKS00021675, date 8 May 2020).

Patients and the public were not involved in this study.

COVID-19 ED workflow model Essen {#Sec4}
--------------------------------

To establish a central COVID-19 pandemia care center within the city of Essen (560,000 inhabitants), the university hospital was required to develop a safe and efficient workflow in the emergency department.

A separate outpatient COVID-19 ED was established next to the non-trauma ED for all walking patients with quick workflow filtering out those who need inpatient care. To streamline patient workup, the existing ED isolation capacities were extended by a fourteen bed holding area for patients under evaluation for COVID-19; three more isolation units were established for those with proven COVID-19 disease, as well as a separate intermediate care unit and ICU with ECMO available (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Structure of ED during COVID-19 pandemia

Our workflow (Fig. [2](#Fig2){ref-type="fig"}) combines a definite diagnosis/rule out strategy for COVID-19 with a high level of isolation measures. All patients with symptoms suggestive of COVID-19 were isolated upon arrival to the ED. After initial triage and vital parameters, unstable patients were transferred to a shock room/ COVID-19 ICU. Fig. 2Workflow inpatient COVID-19

All patients were tested for COVID-19 by a SARS-Cov-2 nasopharyngeal swab (ViroCult®, Medical Wire & Equipment Co. Ltd., Corsham, Wiltshire, UK). To detect SARS-CoV-2, a RT-PCR (SARS-CoV-2 RT-PCR Kit 1.0, Altona Diagnostics GmbH, Hamburg, Germany) was performed \[[@CR11]\]. Additional laboratory testing and CT pulmonary angiography were performed when symptoms of lower respiratory tract involvement occurred. Retesting or additional bronchoscopy/ CT scan could be added in case of ongoing suspicion and negative swab testing. Strict isolation measures were kept until COVID-19 was definitely ruled out. From the onset of pandemia, all ED employees had to wear faceshields and FFP3 masks whenever in contact with any patient irrespective of symptoms suggestive for COVID-19 and keeping distance to each other while wearing a regular mask inside the ED.

Parameters {#Sec5}
----------

We compared and analyzed clinical parameters, Manchester Triage System (MTS) categories, and laboratory parameters between patients with negative and patients with positive swab results for SARS-CoV-2.

Clinical parameters were symptoms upon arrival comprising dyspnea, sore throat, cough, fever, headache, fatigue, myalgia, chest pain, nausea, diarrhea, and dysgeusia.

Laboratory results were white blood cell count, lymphocytes, C-reactive protein, procalcitonine, glomerular filtration rate, creatinine, troponine, and D-dimers.

Patient data were obtained through the electronic medical record (ERPath, eHealth-Tec Innovations GmbH, Berlin, Germany; Medico, Cerner Health Services GmbH, Idstein, Germany).

Missing data that could not be extracted from patients' records were excluded from statistical analysis.

Statistical analyses {#Sec6}
--------------------

We used a *t* test to evaluate metric data. Data were tested by Levene's test to assess the equality of variances. In case of unequal variances, Welch's *t* test was performed to analyze metric data. Results were reported as mean ± standard deviations for continuous variables. Pearson's *x*^2^ test or the Fisher's exact test was used to evaluate categorical data. Results for categorical variables were reported as percentages. All data were analyzed using SPSS, version 26 (IBM, Armonk, NY, USA). Statistical significance was defined as two-tailed *p* \< 0.05.

Results {#Sec7}
=======

A total of 314 patients (mean age 66 ± 17.7 years; 118 female (37.6%)) were included in the analysis. Baseline characteristics are summarized in Table [1](#Tab1){ref-type="table"}*.* According to the MTS, 52 patients were classified as "red" (16.6%), 28 patients as "orange" (8.9%), 118 patients as "yellow" (37.8%), 111 patients as "green" (35.4%), and 3 patients as "blue" (1.0%). Table 1Characteristics of patients who were admitted to the emergency department due to symptoms suspicious for COVID-19All (*n* = 314)COVID-19 pos. (*n* = 43)No-COVID-19 (*n* = 271)*p* valueAge, mean (± SD, range)66 (± 17.72, 22--97)71 (± 17.03; 23--94)65 (± 17.70; 22--97)0.057Male gender, *n* (%)196 (62.4)28 (65.1)168 (62.0)0.694Manchester triage, *n* (%) Red52 (16.6)4 (9.3)48 (17.7)0.160 Orange28 (8.9)3 (7.0)25 (9.2)0.622 Yellow118 (37.8)13 (30.2)105 (39.0)0.269 Green111 (35.4)23 (53.5)88 (32.5)0.008 Blue3 (1.0)0 (0)3 (1.1)0.487

Forty-three patients (13.7%) were tested positive for SARS-Cov-2 by nasopharyngeal swab. Results after comparison of the COVID-19 patients and the patients with negative swab are listed in Table [2](#Tab2){ref-type="table"}. Table 2Comparison of patients with symptoms suspicious for COVID-19 with proven infection vs negative test resultAll (*n* = 314)COVID-19 pos. (*n* = 43)No-COVID-19 (*n* = 271)*p* valueMedical history positive for, *n* (%) Cardiac208 (66.5)28 (65.1)180 (66.7)0.841 Pulmonary96 (30.7)10 (23.3)86 (31.9)0.256 LAE/thrombosis24 (7.7)2 (4.7)22 (8.1)0.423 Renal77 (24.6)4 (9.3)73 (27.0)0.012 Cancer84 (26.8)10 (23.3)74 (27.4)0.568Smoker, *n* (%) Never57 (18.2)9 (20.9)48 (17.7)0.611 Yes38 (12.1)1 (2.3)37 (13.7)0.034 Quitted31 (9.9)3 (7.0)28 (10.3)0.493 Unknown188 (59.9)30 (16.0)158 (58.3)0.154Symptoms, *n* (%) Dyspnea151 (48.1)18 (41.9)133 (49.1)0.379 Sore throat26 (8.3)4 (9.3)22 (8.1)0.793 Cough134 (42.7)24 (55.8)110 (40.6)0.061 Fever172 (54.8)27 (62.8)145 (53.5)0.256 Headache26 (8.3)5 (11.6)21 (7.7.)0.391 Fatigue162 (51.6)22 (51.2)140 (51.7)0.920 Myalgia47 (15.0)5 (11.6)42 (15.5)0.509 Chest pain22 (7.0)1 (2.3)21 (7.7)0.196 Nausea68 (21.7)5 (11.6)63 (23.2)0.086 Diarrhea74 (23.6)11 (25.6)63 (23.2)0.738 Dysgeusia10 (3.2)6 (14.0)4 (1.5)0.001Treatment, *n* (%) O~2~ therapy95 (30.4)18 (41.9)77 (28.5)0.077 Ventilator12 (3.8)3 (7.0)9 (3.3)0.278 Intensive care54 (17.2)4 (9.3)50 (18.5)0.140 Intermediate care28 (8.9)4 (9.3)24 (8.9)0.924 Time of admission7.3 (7.2)8.6 (8.3)7.1 (7.0)0.214Vital parameters Respiratory rate/min (± SD)22 (± 8)23 (± 7)22 (± 8)0.149 Heart rate/min (± SD)97 (± 22)93 (± 17)97 (± 23)0.271 Saturation, O~2~ in % (± SD)94 (± 7)95 (± 4)94 (± 7)0.479 Temperature in °C (± SD)37.2 (± 1.3)37.3 (± 1.0)37.2 (± 1.3)0.916 BP systolic in mmHg (± SD)132 (± 26)137 (± 25)131 (± 26)0.172 BP diastolic in mmHg (± SD)80 (± 21)84 (± 18)80 (± 21)0.250Laboratory values C-reactive protein, mg/L8.96 (± 8.41)8.28 (± 5.71)9.07 (± 8.78)0.446 Procalcitonin, μg/L (± SD)3.96 (± 28.26)0.68 (± 1.98)4.51 (± 30.52)0.429 Troponin I, μg/L (± SD)360.42 (± 3846.98)81.03 (± 286.99)410.94 (± 4178.37)0.656 LDH, U/L (± SD)398.70 (± 427.95)435.31 (± 268.11)393.03 (± 447.75)0.567 Creatinine, mg/dL (± SD)1.37 (± 1.18)1.20 (± 0.93)1.40 (± 1.22)0.309 GFR, mL/min (± SD)56 (± 23)59 (± 21)55 (± 23)0.385 D-dimer, mg/L (± SD)4.45 (± 7.97)4.52 (± 8.15)4.44 (± 7.96)0.957 WBC/mm^3^ (± SD)11.25 (± 14.77)8.01 (± 4.24)11.75 (± 15.74)0.127 Lymphocytes/mm^3^ (± SD)1.96 (± 7.59)1.17 (± 1.44)2.10 (± 8.22)0.538

Of the 271 with negative test results, 55 underwent repeated testing due to ongoing suspicion of COVID-19. Two of those 55 (3.6%) revealed to be positive in the course of clinical treatment but were not included in our primary analysis of COVID-19 positive patients.

Of all COVID-19 patients, 14% (6/43) reported dysgeusia, while this clinical feature was only present in 1.5% (4/271) of non-COVID-19 patients (*p* = 0.001). Significant differences between the two groups were not observed for other clinical features (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Clinical symptoms

Patients with COVID-19 had significantly less preexisting renal disorders (9.3% vs 27.0%; *p* value 0.012). No significant differences were observed for the presence of a preexisting cardiac or pulmonary disorder, previous thrombosis, or pulmonary embolism and oncological diseases between COVID-19-positive and COVID-19-negative patients.

There were significantly more active smokers in the non-COVID-19 group than in the group with COVID-19-positive patients (13.7% vs 2.3%; *p* = 0.034). However, the number of patients with an unknown smoking status was, although not significantly, also higher in the non-COVID-19 group than in the group tested positively (58.3% vs 16.0%; *p* = 0.154).

The mortality of COVID-19 patients admitted to our hospital via the ED was 18.6%, which was not significantly higher than patients admitted with similar symptoms but negative COVID-19 result (11.1%) (*p* = 0.159).

In the group of the COVID-19 patients, 18 patients (41.9%) were treated with oxygen upon admission in the emergency department. However, this was not significantly different to the 77 patients (28.5%) of the non-COVID-19 group who were supported with oxygen.

We could not find any significant differences regarding to vital parameters and laboratory values between the two groups (Table [2](#Tab2){ref-type="table"})

Discussion {#Sec8}
==========

Forty-three patients (13.7%) of our 314 patients were tested positive for COVID-19 by pharyngeal swab.

In our study, dysgeusia was the only clinical finding that was significantly more frequent in COVID-19 patients. Unfortunately, we did not identify further clinical findings, laboratory parameters, or vital signs to distinguish between patients positive for COVID-19 and the negative tested ones.

Gao et al. showed significant differences in D-Dimer and C-reactive protein (CRP) between mild and severe cases of COVID-19 \[[@CR12]\]. Also, lymphopenia and higher LDH values have been described to be associated with higher rate of ICU admissions in patients with COVID-19 \[[@CR13]\]. Mardani et al. published a small study with 200 patients in which they suggest that level of LDH, CRP, ALT, and neutrophils could be used to predict the result of COVID-19 test \[[@CR14]\]. However, convincing data of larger studies that show the use of predicting laboratory parameters are sparse.

In our study, we observed three findings that seemed to be associated with COVID-19: Patients with COVID-19 had more often dysgeusia. Six COVID-19 patients (14.0%) reported this symptom, whereas only 4 (1.5%) of the non-COVID-19 group. Reduced olfaction and decreased sense of taste was reported especially after the viral outbreak reached Europe and might be quite pathognomonic for COVID-19 \[[@CR15], [@CR16]\]. However, dysgeusia was only present in a small proportion of cases and, thus, is a specific but not sensitive symptom.Interestingly, in this study, a history of renal failure was associated with a lower likelihood to be tested positive for COVID-19. This result does not match with the current literature. In previous studies, medical history of immunosuppressive and cardiovascular diseases, including renal disorders, shows a higher risk for severe COVID-19 infection and need for hospital admission in COVID-19 patients \[[@CR5], [@CR6]\]. However, in our cohort, patients with positive COVID-19 test were, even if not significantly, younger compared to the negative group. In general, older patients are more likely to have renal disorders \[[@CR17]\], and thus, patient age might serve as a confounder in our analysis. Gao et al. found an association with the treatment of hypertension and severe COVID-19 infection, including COVID-19 mortality \[[@CR18]\]. In their study, antihypertensive treatment seems to protect patients from severe COVID-19 infection. Hypertension is associated with renal disorders \[[@CR17]\]. In general, patients with renal failure may use more antihypertensive medication than patients without renal disorders. Therefore, this medication could protect them from severe COVID-19 infection needing hospital admission. However, we are aware that this is daring thesis and larger studies are needed to elucidate the complex interaction of renal function, antihypertensive medication, and COVID-19 infection.In our study, there tended to be less active smokers in the COVID-19 group than in the non-COVID-19 group. Only one out of 43 positive patients reported to be a current smoker, while 13.7% of the non-COVID-19 patients announced to smoke regularly by the time of infection. Smoking has been assumed to be possibly associated with adverse disease prognosis, as extensive evidence has highlighted the negative impact of tobacco use on lung health and previous studies have shown that smokers are more vulnerable to infectious diseases and were also noted to have higher mortality in the previous MERS-CoV outbreak \[[@CR19], [@CR20]\]. Most studies examining smoking on patients with COVID-19 assume that smoking is most likely associated with the negative progression and adverse outcomes of COVID-19 \[[@CR6], [@CR9], [@CR21]\].

Even during the peak of local pandemia, the rate of proven COVID-19 did not exceed 13.7% among all patients presenting with suggestive symptoms. We expect this rate to decrease further in the months to come.

Typical ED diagnoses as decompensated heart failure, pneumonia, exacerbated chronic obstructive lung disease, or gastroenteritis present with symptoms suggestive for COVID-19 and can therefore be very misleading. COVID-19 is able to mimic many other common diseases and many unusual clinical presentations have been reported from all over the world \[[@CR22]\].

The established workflow of our hospital (Fig. [2](#Fig2){ref-type="fig"}) was able to prevent spreading of the virus and thereby protect ED staff and non-COVID-19 patients. Voluntary antibody testing of 316 employees of the university hospital during the peak of the pandemia in Essen revealed only three AB positive healthcare workers out of 244 exposed high-risk workers (1.2%) in ED, COVID-19 wards, and COVID-19 ICU as recently published from our institution \[[@CR23]\].

Following the high number of patients presenting with possible symptoms of COVID-19 to the ED, only strict isolation and protection measures in line with a broad swab testing will prevent spreading of the virus and maintain safety of ED staff. A validated fast SARS-Cov-2-PCR POCT would be extremely helpful to save health care resources.

Limitations {#Sec9}
===========

Our study has few limitations. Data collection was retrospective. Therefore, selection bias and errors in data entry could not be completely excluded. Furthermore, this study is a single-center study, and for these reason, data should not be generalized.

Another limitation is the single testing in SARS-Cov-2-negative patients, who mostly got no repeated testing, so there could have been some more SARS-Cov-2-positive patients than numbered.

We often saw patients with advanced disease in our emergency department. Severe disease of COVID-19 often starts in the second week after infection when the virus and antigen-antibody complexes affect the lungs and other parts of the body, and viral RNA often cannot be detected in the nasopharyngeal swab \[[@CR24]\]. Therefore, a certain number of false negative tests should be taken into account.

Furthermore, we included only inpatient patients. As SARS-Cov-2 is often associated with minor symptoms or illness, the number of outpatient treatment could have been higher than in non-COVID-19 respiratory infections.

In our cohort, the number of patients with unknown smoking status is very high (59.9%). Therefore, in this study, it seems to be difficult to evaluate the exact number of current smokers. We think that this might be the reason for the paradoxical finding that a history of smoking was more frequent in the non-COVID-19 group.

Conclusion {#Sec10}
==========

Many severely ill patients presenting to the ED show symptoms suggestive of COVID-19. Even during the peak of pandemia, only 13.7% (43/314) of these patients proofed positive for COVID-19 in our study. Neither laboratory nor vital parameters nor clinical symptoms can be used to predict COVID-19-positive test results. When present, dysgeusia should raise a high suspicion of COVID-19 during pandemia. Further studies with bigger numbers are needed to evaluate predictors for COVID-19 to help to optimize triaging patients in the ED. Strict isolation and personal protection policy together with broad testing of patients under evaluation is needed for the months to come.
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